Forbion closes Life Sciences VC Fund at 360m
Life Sciences venture capitalist Forbion has closed its new flagship fund, Forbion IV, at 360m, 90m above its original target of 250m.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1116 entries already.
Entries by Thomas Gabrielczyk
BIOSPAIN expanding
/in News/by Thomas GabrielczykMatured, diversified and willing to expand this is how the Spanish biotech sector presented itself during BIOSPAIN 2018 in Seville. Andalusia has launched the first bioeconomy policy strategy in […]
Minoryx bags 21.3m Series B financing
/in News/by Thomas GabrielczykBarcelona-based Minoryx Therapeutics announced during BIOSPAIN 2018 it has raised another 21.3m in a Series B financing bringing its assets to a total of 50M.
PD-1+ T cells trigger pulmonary fibrosis
/in News/by Thomas GabrielczykA team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells.
CRISPR-gene drive safely kills mosquitos
/in News/by Thomas GabrielczykA new gene drive can cause the complete collapse of caged malaria-carrying mosquito populations, researchers from Imperial College report in Nature Biotechnology.
CHMP with new Chair 13 meds recommended
/in News/by Thomas GabrielczykThe CHMP elected Harald Enzmann as its new Chair on Friday, and recommended thirteen medicines for approval, three thereof orphan medicines.
European biotech companies enter IPO prep course
/in News/by Thomas GabrielczykEuropean stock exchange operator Euronext kicked off its fourth annual capital markets training programme for non-listed companies this time also including companies from Germany, Italy, Spain, and Switzerland.
Novo Nordisk reveals details about its R&D transformation
/in News/by Thomas GabrielczykNovo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark and […]
Pharming receives complete response letter from FDA
/in News/by Thomas GabrielczykThe FDA has requested additional clincal data demonstrating that Pharming Group’s recombinant C1 esterase blocker Ruconest can prevent hereditary angioedema attacks (HAE).
CRISPR Therapeutics and Viacyte launch diabetes partnership
/in News/by Thomas GabrielczykCRISPR Therapeutics AG announced a development partnership with ViaCyte Inc to develop genome-edited pancreatic islet cells, which do not require immunosuppression, to treat diabetes.